NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Sandoz's Strategy for the 'Golden Decade' of Affordable Medicines
TL;DR
Sandoz plans to capture significant market share from over $600 billion in medicines losing exclusivity, positioning investors for advantage in the coming golden decade.
Sandoz executes its strategy through $1.1 billion in facility investments, 13 biosimilar molecules across 100 countries, and a pipeline targeting 60% of the $322 billion biosimilar opportunity.
Sandoz aims to make healthcare more accessible by providing affordable medicines for 900 million patient treatments, reducing costs while maintaining quality and safety standards.
Sandoz pioneered the world's first biosimilar in 2006 and now leads in affordable medicines, with 1,300 products supplied to over 100 countries globally.
Found this article helpful?
Share it with your network and spread the knowledge!
Sandoz CEO Richard Saynor will present plans at the 44th Annual J.P. Morgan Healthcare Conference to capitalize on an unprecedented 'golden decade' market opportunity where medicines worth over $600 billion lose exclusivity, aiming to increase patient access to affordable medicines.
Because medicines worth more than USD 600 billion are due to lose exclusivity over the next decade, creating an unprecedented market opportunity for affordable biosimilar and generic medicines that Sandoz plans to capture.
In its first two years as a standalone company, Sandoz has consistently delivered on commitments, including six biosimilar launches in 2025, major facility investments totaling over $1.35 billion, and achieving $10 billion in 2024 sales with strong double-digit growth.
Sandoz's leadership is defined by its global scale (1,300 products to over 100 countries), unique positioning as the only 'pure-play' biosimilar and generic company, and its respected leadership team backed by over 20,000 employees worldwide.
CEO Richard Saynor will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 18:45 CET (9:45 PST), with the conference running from January 12 to 15.
Sandoz has invested over $1.1 billion in a new sterile biosimilars production center in Slovenia, completed acquisition of Just-Evotec Biologics' site in France, and invested $250 million in its vertically-integrated European penicillin production network.
Sandoz is the global leader in the affordable medicines industry, which accounts for 80% of medicines used at just 30% of total cost, and leads the global biosimilar and generic market valued at over $250 billion in sales.
CEO Richard Saynor is leading the presentation and strategy, highlighting the company's progress as a standalone company since 2023 and its plans to capitalize on the upcoming market opportunity.
Sandoz's strategy aims to significantly increase patient access to affordable medicines by capturing a major share of the $600+ billion market opportunity as medicines lose exclusivity, making healthcare more accessible worldwide.
Curated from NewMediaWire
